Curated News
By: NewsRamp Editorial Staff
April 24, 2026
Scinai Immunotherapeutics Raises $2.61M to Boost CDMO and Pipeline
TLDR
- Scinai raises $2.6M to expand its CDMO platform, boosting its capacity to serve biotech clients.
- Scinai sold 5.2M ADSs at $0.48 each with warrants, plus a warrant inducement, for $2.61M gross proceeds.
- Scinai's funding advances immunotherapy treatments, potentially improving lives of patients with immune disorders.
- Scinai's stock deal includes warrants exercisable at $0.60, offering investors a potential upside.
Impact - Why it Matters
This funding round is crucial for Scinai Immunotherapeutics as it provides the capital needed to expand its CDMO platform, which is a key revenue driver and service offering. For investors, this signals the company's focus on operational growth and pipeline advancement, potentially enhancing its market position. The proceeds will also support customer programs, indicating a commitment to serving the broader biotech ecosystem. In a competitive industry, such strategic investments can differentiate Scinai and drive long-term value.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) has announced a significant capital raise through a securities purchase agreement with institutional and accredited investors. The company will sell 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, along with accompanying Series A and Series B warrants. Additionally, Scinai executed a warrant inducement agreement with an existing investor. These combined transactions are expected to generate approximately $2.61 million in gross proceeds, with the closing anticipated on or about April 27, 2026, subject to customary conditions. The funds will be used to support the expansion of Scinai's CDMO platform, advance customer programs, and continue investment in its immunotherapy pipeline.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. It also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides development and manufacturing services to biotechnology and pharmaceutical companies. This capital infusion is a strategic move to bolster the company's capabilities and accelerate its growth in the competitive biotech landscape.
The news was disseminated through BioMedWire, a specialized communications platform that focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which offers a range of services including wire solutions via InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution. For investors seeking the latest news and updates regarding SCNI, they are available in the company's newsroom at https://ibn.fm/SCNI. This funding round highlights Scinai's commitment to expanding its CDMO operations and advancing its pipeline, positioning the company for future growth.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Raises $2.61M to Boost CDMO and Pipeline
